Roquefort Therapeutics (LON:ROQ) Trading Down 15.2% – Here’s What Happened

Roquefort Therapeutics plc (LON:ROQ)’s stock price traded down 15.2% during trading on Tuesday . The stock traded as low as GBX 1.48 ($0.02) and last traded at GBX 1.60 ($0.02). 6,200,585 shares changed hands during trading, an increase of 221% from the average session volume of 1,934,276 shares. The stock had previously closed at GBX 1.89 ($0.02).

Roquefort Therapeutics Trading Up 4.8 %

The company has a quick ratio of 3.07, a current ratio of 0.79 and a debt-to-equity ratio of 12.37. The firm’s 50-day moving average price is GBX 3.12 and its 200 day moving average price is GBX 3.69. The company has a market capitalization of £2.07 million, a P/E ratio of -1.34 and a beta of 0.05.

Insider Transactions at Roquefort Therapeutics

In other news, insider Stephen Paul West purchased 400,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 4th. The shares were acquired at an average cost of GBX 3 ($0.04) per share, for a total transaction of £12,000 ($15,467.90). 60.40% of the stock is currently owned by insiders.

About Roquefort Therapeutics

Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.